Serwis Infona wykorzystuje pliki cookies (ciasteczka). Są to wartości tekstowe, zapamiętywane przez przeglądarkę na urządzeniu użytkownika. Nasz serwis ma dostęp do tych wartości oraz wykorzystuje je do zapamiętania danych dotyczących użytkownika, takich jak np. ustawienia (typu widok ekranu, wybór języka interfejsu), zapamiętanie zalogowania. Korzystanie z serwisu Infona oznacza zgodę na zapis informacji i ich wykorzystanie dla celów korzytania z serwisu. Więcej informacji można znaleźć w Polityce prywatności oraz Regulaminie serwisu. Zamknięcie tego okienka potwierdza zapoznanie się z informacją o plikach cookies, akceptację polityki prywatności i regulaminu oraz sposobu wykorzystywania plików cookies w serwisie. Możesz zmienić ustawienia obsługi cookies w swojej przeglądarce.
Development and application of a high‐throughput microneutralization assay: lack of xenotropic murine leukemia virus–related virus and/or murine leukemia virus detection in blood donors
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
From the Blood Systems Research Institute, and the Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California; Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; Creative Testing Solutions, Tempe, Arizona; the Hospital for Sick Children, Toronto, Ontario, Canada; and the Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.